The US Food and Drug Administration (FDA) has approved the B-cell depleting agent inebilizumab-cdon (Uplizna, Amgen) for the treatment of immunoglobulin G4-related disease (IgG4-RD). This is the first and only treatment approved for this rare autoimmune disease in the United States. An estimated 200,000 people in the United States are living with IgG4-RD...
.png)
55W 14th St Ste 101, Helena, MT, 59601 US
+1 (406) 319 1601
news.in.usa@olahost.top
Copyright © 2024 olasport. All Rights Reserved
